{"id":22184,"date":"2024-10-16T09:01:50","date_gmt":"2024-10-16T09:01:50","guid":{"rendered":"https:\/\/clinlabint.com\/?p=22184"},"modified":"2024-10-16T09:01:50","modified_gmt":"2024-10-16T09:01:50","slug":"beckman-coulter-and-scopio-labs-add-worlds-first-digital-bone-marrow-imaging-and-analysis-to-long-term-partnership","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/beckman-coulter-and-scopio-labs-add-worlds-first-digital-bone-marrow-imaging-and-analysis-to-long-term-partnership\/","title":{"rendered":"Beckman Coulter and Scopio Labs Add World\u2019s First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership"},"content":{"rendered":"
\n

\r\n\"Forum<\/a>\r\n<\/div><\/p>\n<\/div><\/section><\/div>

\r\n\r\n\"\"<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\n

Beckman Coulter and Scopio Labs Add World\u2019s First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio\u2019s Full-Field Bone Marrow Aspirate\u2122 (FF-BMA) Application. Scopio\u2019s X100 \/ X100HT with FF-BMA Application are CE-Marked.<\/h3>\n

<\/p>\n

Bone marrow aspirate analysis is a vital procedure providing essential information for the assessment of various hematologic diseases.[i]<\/a> By aspirating a small sample of the liquid portion of bone marrow, clinicians can examine the cellular composition, as well as the morphology and maturity of the blood cells morphology. However, traditional BMA analysis uses manual, labor-intensive, time-consuming methods that are heavily reliant on highly skilled hematopathologists to ensure accuracy.<\/p>\n

Scopio\u2019s FF-BMA Application transforms BMA analysis by combining high-resolution Full-Field imaging with a robust AI-powered decision support system into a fully digital workflow seamlessly integrated with Scopio\u2019s X100 and X100HT scanners. It also enables hematopathologists to review bone marrow smears remotely (via a secure hospital network), potentially reducing turnaround time, fostering collaboration, facilitating second opinions, and bolstering diagnostic confidence.<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
\"\"<\/div><\/div><\/div>
\n
<\/span><\/span><\/div>
\n

\u201cIn today\u2019s lab, there is limited technology available to assist in the analysis of bone marrow aspirate,\u201d said Chris Hagen, Senior Vice President and General Manager, Core Lab Specialty Products for Beckman Coulter Diagnostics. \u201cWith Scopio\u2019s technology, lab scientists can assess hundreds of cells to evaluate morphological features with the support of artificial intelligence using the world\u2019s first BMA digital imaging and analysis solutions. \u00a0Reviewers can observe representative cell distribution across the sample at rates far exceeding that of reviews done by manual microscopes. We are thrilled to expand our partnership with Scopio and continue to bring full-field, AI-powered, digital imaging innovations to clinical labs worldwide.\u201d<\/p>\n

\u201cWe are excited to extend our global partnership agreement with Beckman Coulter, which exemplifies our shared mission to advance the digital transformation of clinical laboratories around the world,\u201d said Itai Hayut, CEO and Co-Founder of Scopio Labs. \u201cThe addition of our first-of-its-kind digital bone marrow application into Beckman Coulter\u2019s hematology offering, signifies a strong endorsement of the successful adoption of Scopio’s Full-Field digital cell morphology platform in the market to date. We look forward to continuing our partnership as Scopio brings new products to the market to fulfill the potential of hematology diagnostics in this new digital era.\u201d<\/p>\n

Since 2022, Beckman Coulter and Scopio have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio\u2019s X100 and X100HT digital cell morphology platforms employ full-field imaging and AI decision support eliminating the need for manual microscopy, while providing laboratory scientists and physicians true workflow benefits with simple to use remote viewing through a secured network.<\/p>\n

In 2023, Beckman Coulter Diagnostics announced a new end-to-end automated hematology solution by connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with the Scopio X100HT high-throughput digital cell morphology platform, complete with digitalized, AI-assisted peripheral blood smear analysis.<\/p>\n

Availability of Scopio Labs\u2019 Full-Field Peripheral Blood Smear\u2122 Application and Full-Field Bone Marrow Aspirate\u2122 Application may vary by region. To learn more, visit www.scopiolabs.com<\/a><\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n